385 related articles for article (PubMed ID: 30457649)
1. Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity.
Theophanous C; Schechet S; Rodriguez SH; Blair M
Ophthalmic Surg Lasers Imaging Retina; 2018 Nov; 49(11):893-896. PubMed ID: 30457649
[TBL] [Abstract][Full Text] [Related]
2. Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study.
Morrison D; Shaffer J; Ying GS; Binenbaum G;
J AAPOS; 2018 Apr; 22(2):128-133. PubMed ID: 29548840
[TBL] [Abstract][Full Text] [Related]
3. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab.
Hajrasouliha AR; Garcia-Gonzales JM; Shapiro MJ; Yoon H; Blair MP
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):255-259. PubMed ID: 28297039
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review.
Frosini S; Franco F; Vicini G; Nicolosi C; Varriale G; Dani C; Virgili G; Giansanti F
J Matern Fetal Neonatal Med; 2022 Sep; 35(17):3337-3342. PubMed ID: 32933350
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.
Nazari H; Modarres M; Parvaresh MM; Ghasemi Falavarjani K
Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1713-8. PubMed ID: 20582706
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
9. Late-onset tractional fibrovascular proliferation post-intravitreal bevacizumab following treatment of retinopathy of prematurity.
Agarwal-Sinha S; Guevara JG; Amin SM
Can J Ophthalmol; 2018 Jun; 53(3):e99-e103. PubMed ID: 29784188
[No Abstract] [Full Text] [Related]
10. Persistent Angiographic Abnormalities After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
Shah N; Gupta MP; Chan RVP
JAMA Ophthalmol; 2018 Apr; 136(4):436-437. PubMed ID: 29285531
[No Abstract] [Full Text] [Related]
11. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
12. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.
Akdogan M; Cevik SG; Sahin O
Indian J Ophthalmol; 2019 Jun; 67(6):879-883. PubMed ID: 31124508
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal injection of bevacizumab for retinopathy of prematurity.
Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
[TBL] [Abstract][Full Text] [Related]
14. Playing With Fire.
Harper CA; Beck KD; Chang E; Young R; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2020 Oct; 51(10):542-544. PubMed ID: 33104220
[TBL] [Abstract][Full Text] [Related]
15. RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY: A Longitudinal Fluorescein Angiographic Study.
Lorenz B; Stieger K; Jäger M; Mais C; Stieger S; Andrassi-Darida M
Retina; 2017 Jan; 37(1):97-111. PubMed ID: 27454223
[TBL] [Abstract][Full Text] [Related]
16. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
[TBL] [Abstract][Full Text] [Related]
17. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
[TBL] [Abstract][Full Text] [Related]
18. Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP.
Lepore D; Ji MH; Quinn GE; Amorelli GM; Orazi L; Ricci D; Mercuri E
Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):180-186. PubMed ID: 32211908
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
[TBL] [Abstract][Full Text] [Related]
20. Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?
Dikci S; Ceylan OM; Demirel S; Yılmaz T
Arq Bras Oftalmol; 2018; 81(1):12-17. PubMed ID: 29538588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
